Introduction {#Sec1}
============

Renal cell carcinoma (RCC) is one of the most common genitourinary malignancies, accounting for about 3 % of all cancers worldwide \[[@CR1]\]. Clear cell renal cell carcinoma (ccRCC) is the most common histological type of renal cell carcinoma, also called conventional RCC, which represents 75--80 % of RCC. The male/female ratio is approximately 2:1 \[[@CR2]\]. Initial treatment is most commonly a radical or partial nephrectomy and remains the mainstay of curative treatment \[[@CR3]\]. Where the tumor is confined to the renal parenchyma, the 5-year survival rate is 60--70 %, but this is lowered considerably where metastases have spread. It is relatively resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy.

After the completion of the Human Genome Project, advances in microarray technology led to global gene expression profiling of ccRCC \[[@CR4]--[@CR6]\]. Microarray technology profiles the expression levels of thousands of genes simultaneously, providing a snapshot of transcript levels in the cells/tissues being studied; it is a powerful tool to study ccRCC. All microarray data are available from the Gene Expression Omnibus (GEO) public database at NCBI \[[@CR7]\]. However, the large amounts of data acquired must be reduced or 'translated' to a smaller set of genes representing meaningful biological differences between control and test systems and validated in an experimental or clinical setting. It is a challenge to analyze such high information from microarray datasets to identify molecular pathways and key genes deregulated in ccRCC. To resolve this conflict, Subramanian describes a method gene set enrichment analysis (GSEA) which has been recognized as a breakthrough for the gene set and functional pathways analysis \[[@CR8]\]. GSEA is a method that allows us to search the key genes and pathways associated with the occurrence and development of disease by analyzing diverse experimental datasets. However, the difference of platforms, the sample capacity and the standardization affect the result more or less. Meta-analysis of microarray data can be a better way to solve the problem of poor reproducibility and reliability \[[@CR9]\]. In our study, after a standardized microarray preprocessing for all the expression datasets, GSEA and a meta-analysis were used to detect the mixing pathways and key genes which can provide the theoretical basis to the further perception of the biological mechanism of ccRCC.

Materials and methods {#Sec2}
=====================

Data collection {#Sec3}
---------------

We used clear cell renal cell carcinoma as the keywords and set the limit of study type expression profiling by array and a species limit of humans to search GEO (<http://www.ncbi.nlm.nih.gov/geo/>) for the relevant gene datasets. Search results provided 2,762 identified datasets involved in ccRCC. Studies that met all of the following criteria were included: (1) the data were about genome-wide RNA expression; (2) the complete microarray raw or normalized data were effective; (3) the data provided a comparison of renal tissue between ccRCC patients and normal controls relatively; (4) datasets contained more than three samples; (5) the raw data were expressed as CEL files. Finally, there were three gene expression datasets which met the selection criteria (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of datasets selected in the studiesGEO accessionContributorYearsChipExperimental designProbsSourceDiseaseNormalGSE781Lenburg ME2003HG-U133APaired, tissues22,283Homo sapiens77GSE6344Gumz ML2007HG-U133APaired, tissues22,283Homo sapiens1010GSE36895Peña-Llopis S2012HG-U133_Plus_2Paired, tissues54,675Homo sapiens2323Paired = compare clear cell renal carcinomas to normal controls from the same patients with clear cell renal carcinoma

Gene set enrichment analysis {#Sec4}
----------------------------

The category version 2.10.1 package was used to perform with GSEA. General statistical analysis and computing was processed in the R statistical programming language \[[@CR10]\]. The Robust Multichip Averaging (RMA) \[[@CR11]\] algorithm in the affy conductor package \[[@CR12]\] was used for each affymetrix raw dataset to calculate background-adjusted, normalized and log2 probe set intensities. The only genes we selected should have been mapped to an explicit KEGG pathway for the purpose of analyzing the GSEA and meta-analysis further \[[@CR13]\]. We performed pathway analysis of each dataset independently. The measure of variability was within the interquartile range (IQR) and a cut-off was set up to remove IQR values under 0.5 for all the remaining genes. If one gene was targeted for multiple probe sets, we retained the probe set with the largest variability. Genes in each pathway went through the Student's *t* test, and each pathway's *p* value was obtained in the permutation test with 1,000 times. The *p* value was not more than 0.05.

Meta-analysis {#Sec5}
-------------

To obtain the differentially expressed genes from the remaining genes of each dataset above, meta-analysis was carried out in SAS 9.13. The following formula was applied to calculate chi-square value of each gene \[[@CR14]\]:$$\documentclass[12pt]{minimal}
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                \usepackage{wasysym} 
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                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ X^{2} = - 2\sum\limits_{i = 1}^{\text{k}} {\log_{\text{e}} P^{\text{i}} } $$\end{document}$$(K is the number of the datasets).

To calculate *p* value of each gene, and retained the genes with *p* \< 0.05. Significant genes were used to obtain the pathways of the KEGG from DAVID Bioinformatics Resources 6.7 (<http://david.abcc.ncifcrf.gov/>).

Results {#Sec6}
=======

GSEA analysis {#Sec7}
-------------

According to the inclusion criteria, we obtained three datasets in the end. Tissues used to extract the total RNA were matched pairs from clear cell renal cell carcinoma and normal tissue adjacent to renal cell carcinoma. The fuhrman grade of ccRCC was no more than three. Due to the samples used, genomic profiling were matched pairs. It reduced the influence of multiple factors on GSEA and Meta-analysis, ensuring the reliability of the obtained conclusion.

The three inclusion datasets contained 40 ccRCC cases and 40 controls. GSEA method was used separately on each dataset to find the significantly changed genes and the significant co-pathways. After GSEA analysis, 8,506 significantly changed genes were screened out from the three gene expression microarray datasets. Overlap existed in the up-regulated and down-regulated pathways. There were fourteen mixing pathways including 206 up-regulated and 253 down-regulated pathways from three datasets. Detailed information about the analysis results is shown in Table [2](#Tab2){ref-type="table"}.Table 2Summary of each dataset used gene set enrichment analysis (GSEA)StudiesNumber of patientsNumber of controlsNumber of significantly changed genes after GSEAUp-regulated pathwaysDown-regulated pathwaysGSE781772,6897357GSE634410102,6446896GSE3689523233,17365100

Meta-analysis {#Sec8}
-------------

To further identify the results above, meta-analysis was used to detect differentially expressed genes between two experimental groups. We got the *p* value for each gene based on unpaired *t* test. A total of 1,150 significant genes were detected (*p* \< 0.05). Furthermore, the Database for Annotation, Visualization and Integrated Discovery (DAVID) (<http://david.abcc.ncifcrf.gov/>) was utilized for the annotation of these genes. We imported the official gene symbols of 1,150 genes into the gene functional classification tool of DAVID. In order to identify biologically relevant molecular networks of these genes, KEGG (<http://www.genome.jp/kegg/>), a distinct pathway analysis tools of bioinformatics endowed with comprehensive knowledgebase was used. There were 1,038 genes identified by KEGG. In total, 48 KEGG pathways were detected. More details were shown in Table [3](#Tab3){ref-type="table"}.Table 3Common significant pathways were obtained from 3 clear cell renal carcinoma tissue datasets by meta-analysisPathway entryPathway names*p* valueNumber of genes expressed in the pathwaysUp- or down-regulated pathwaysmap00280Valine, leucine and isoleucine degradation8.79E−1433Upmap00020Citrate cycle (TCA cycle)1.55E−1024Upmap00010Glycolysis/gluconeogenesis1.41E−0833Upmap00640Propanoate metabolism3.35E−0822Upmap00071Fatty acid metabolism2.58E−0724Upmap00620Pyruvate metabolism1.34E−0623Upmap00650Butanoate metabolism5.21E−0620Upmap00330Arginine and proline metabolism1.16E−0424Upmap00190Oxidative phosphorylation4.13E−0444Upmap00260Glycine, serine and threonine metabolism4.36E−0416Upmap05012Parkinson's disease5.80E−0443Upmap04514Cell adhesion molecules (CAMs)5.95E−0444Downmap03320PPAR signaling pathway6.52E−0427Upmap05416Viral myocarditis0.0010727Downmap00380Tryptophan metabolism0.0011918Upmap04142Lysosome0.0012939Upmap00410beta-Alanine metabolism0.0018312Upmap00100Steroid biosynthesis0.0029210Upmap04610Complement and coagulation cascades0.0036325Upmap00051Fructose and mannose metabolism0.0045115Downmap04612Antigen processing and presentation0.0060528Downmap05219Bladder cancer0.0061117Downmap05212Pancreatic cancer0.0066925Downmap00670One carbon pool by folate0.007829Upmap05330Allograft rejection0.0081915Downmap00310Lysine degradation0.0101717Upmap05110Vibrio cholerae infection0.0122320Upmap00903Limonene and pinene degradation0.012818Upmap05130Pathogenic *Escherichia coli* infection0.0149320Downmap04940Type I diabetes mellitus0.0151016Downmap05010Alzheimer's disease0.0152546Upmap04540Gap junction0.0163128Downmap00630Glyoxylate and dicarboxylate metabolism0.019878Upmap00072Synthesis and degradation of ketone bodies0.021156Downmap05214Glioma0.0220521Downmap05222Small cell lung cancer0.0257126Downmap04512ECM--receptor interaction0.0257126Downmap05120Epithelial cell signaling in helicobacter pylori infection0.0262122Upmap04510Focal adhesion0.0327853Downmap00250Alanine, aspartate and glutamate metabolism0.0367912Upmap04666Fc gamma R-mediated phagocytosis0.0371928Downmap04360Axon guidance0.0381136Downmap04012ErbB signaling pathway0.0387326Upmap05332Graft-versus-host disease0.0403114Downmap05200Pathways in cancer0.0682079Downmap00270Cysteine and methionine metabolism0.0691612Upmap05320Autoimmune thyroid disease0.0801416Downmap05322Systemic lupus erythematosus0.0930727Down

The results of GSEA and meta-analysis {#Sec9}
-------------------------------------

To search the intersection pathways, a comparative analysis was made subsequently between the significant common pathways of GSEA and meta-analysis. At last, 37 consistent pathways and significant genes (*p* \< 0.05) in these pathways were obtained. These pathways mainly concerned metabolism, organismal systems, cellular processes, environmental information processing, and human diseases. The details are shown in Table [4](#Tab4){ref-type="table"}.Table 4Common crossing significant pathways and genes between the results of GSEA and meta-analysisPathway entryPathway namesClassificationUp- or down-regulated*p* valueNumber of key genesIncluded genes (*p* value)map00020Citrate cycle (TCA cycle)Metabolism; carbohydrate metabolismup1.55E−1024DLST(1.58E−05), ACO2(0.009461), SUCLG2(0.001127), ACO1(3.37E−08), SUCLG1(7.68E−13), OGDHL(7.95E−10), ACLY(6.53E−05), OGDH(0.015859), PCK2(3.66E−08), PDHB(3.11E−07), PCK1(8.90E−06), SDHB(0.000273), IDH3G(0.000767), SDHC(0.002922), SDHD(0.002733), DLD(0.001570), IDH2(4.67E−07), IDH1(4.72E−05), PDHA1(3.64E−07), SUCLA2(0.002727), MDH2(0.041430), MDH1(3.71E−05), FH(8.33E−05), PC(2.46E−08)map00071Fatty acid metabolismMetabolism; lipid metabolismup2.58E−0724ACAA2(0.015364), ACOX1(1.77E−07), GCDH(2.55E−07), ACADSB(1.06E−05), ACADM(0.000825), CPT2(0.012060), ACADS(0.000351), EHHADH(0.009979), ADH6(6.28E−10), ECHS1(1.41E−09), ADH1B(1.11E−05), ACAT1(3.35E−05), PECI(0.000010), ALDH3A2(0.001311), CPT1A(0.028547), CYP4A11(3.26E−05), ALDH7A1(0.000678), CYP4A22(5.91E−05), ALDH1B1(1.21E−06), ALDH2(2.04E−05), HADH(0.009979), ALDH9A1(7.68E−06), ACAA1(6.20E−09), ACSL5(0.000549)map00100Steroid biosynthesisMetabolism; lipid metabolismup0.0029210TM7SF2(8.34E−08), CEL(0.000000), EBP(0.000483), CYP27B1(1.05E−07), LIPA(1.42E−08), CYP51A1(0.006793), DHCR7(0.038355), HSD17B7(0.017025), SC5DL(2.60E−05), FDFT1(0.000663)map00190O idative phosphorylationMetabolism; energy metabolismUp4.13E−0444UQCRC1(1.72E−10), NDUFB8(0.026633), ATP5B(0.000024968), COX7B(5.76E−05), ATP5G1(0.000552), ATP6V1B2(0.020631), UQCRFS1(4.82E−08), COX5A(9.06E−06), ATP12A(0.002001), ATP6V1B1(8.54E−11), COX5B(0.005213), ATP5G3(5.48E−05), NDUFB1(1.20E−06), ATP6V0B(3.18E−07), ATP6V0C(0.001556), NDUFS7(0.005646), NDUFS8(0.000199), ATP5L(6.10E−05), NDUFS3(0.001237), ATP6V0D1(0.000687), NDUFS2(9.52E−07), NDUFS1(0.000719), TCIRG1(2.68E−06), NDUFA4(6.21E−12), NDUFA3(0.000707), NDUFA4L2(0.000000), NDUFA6(3.74E−06), COX8A(2.45E−06), ATP6V1H(2.04E−09), NDUFA10(0.002332497), LHPP(1.05E−07), ATP6V1D(2.09E−05), PPA2(0.005748), SDHB(0.000273), ATP6V1A(0.000647), ATP6V0E2(1.46E−07), UQCRH(0.008671), NDUFV1(9.75E−06), SDHC(0.002922), SDHD(0.002733), ATP5C1(2.40E−06), ATP5A1(1.85E−07), ATP6V0A4(1.33E−15), UQCRB(0.000496)map00250Alanine, aspartate and glutamate metabolismMetabolism; amino acid metabolismUp0.0367912GOT2(9.07E−07), GLUL(0.014290), GOT1(0.000478), ASS1(8.40E−11), ALDH5A1(9.42E−06), GLS(0.011416), ABAT(8.77E−11), ALDH4A1(3.26E−08), ASNS(0.005671), ASL(0.001059), AGXT(8.18E−05), DDO(0.002112)map00260Glycine, serine and threonine metabolismMetabolism; amino acid metabolismUp4.36E−0416SHMT1(0.003744), SHMT2(4.22E−08), GATM(0.001104), AMT(3.71E−07), MAOA(0.000363), GCAT(2.42E−06), AGXT(8.18E−05), PIPOX(2.83E−09), GLDC(1.54E−08), ALAS1(4.18E−06), CTH(1.48E−06), DLD(0.001570), PHGDH(1.25E−05), DAO(5.49E−10), PSAT1(0.000768), SARDH(0.000146)map00270Cysteine and methionine metabolismMetabolism; amino acid metabolismUp0.0691612GOT2(9.07E−07), ADI1(6.10E−05), LDHB(9.05E−10), CTH(1.48E−06), LDHA(5.38E−14), AHCY(6.74E−05), GOT1(0.000478), DNMT3L(0.000176), DNMT1(3.44E−06), AHCYL1(7.94E−05), AHCYL2(1.62E−08), MPST(0.000405)map00280Valine, leucine and isoleucine degradationMetabolism; amino acid metabolismUp8.79E−1433HSD17B10(1.92E−07), ACADSB(1.06E−05), EHHADH(0.009979), ECHS1(1.41E−09), ACAT1(3.35E−05), ALDH3A2(0.001311), AUH(3.90E−05), MCCC2(0.01761787), MUT(2.71E−05), IVD(1.36E−05), OXCT1(1.70E−06), MCCC1(0.000919), ACAD8(1.38E−07), HADH(3.58E−10), HMGCL(2.12E−07), ALDH6A1(1.54E−09), ACAA2(0.015364), ACADM(0.000824944), ACADS(0.000351), BCKDHB(1.18E−06), DBT(0.000280), ALDH7A1(0.000678), HMGCS2(0.025830), ALDH1B1(1.21E−06), AOX1(0.000215), DLD(0.001570), ALDH2(2.04E−05), ABAT(8.77E−11), HIBCH(3.29E−05), PCCB(4.63E−09), PCCA(1.72E−07), ALDH9A1(7.68E−06), ACAA1(6.20E−09)map00310Lysine degradationMetabolism; amino acid metabolismUp0.0101717DLST(1.58E−05), GCDH(2.55E−07), EHHADH(0.009979), OGDHL(7.95E−10), AASS(4.95E−05), ECHS1(1.41E−09), OGDH(0.015859), ACAT1(3.35E−05), ALDH3A2(0.001311), PIPOX(2.83E−09), ALDH7A1(0.000678), ALDH1B1(1.21E−06), PLOD2(7.01E−10), PLOD3(2.04E−06), ALDH2(2.04E−05), HADH(3.58E−10), ALDH9A1(7.68E−06)map00330Arginine and proline metabolismMetabolism; amino acid metabolismUp1.16E−0424SAT1(0.003288), ALDH18A1(0.000317), ASS1(8.40E−11), GATM(0.001104), MAOA(0.000363), ASL(0.001059), ALDH3A2(0.001311), CKB(0.017515), GOT2(9.07E−07), ALDH7A1(0.000678), GLUL(0.014290), GOT1(0.000478), P4HA2(0.042440), P4HA1(5.46E−10), ALDH1B1(1.21E−06), CKMT2(6.95E−06), ARG2(1.53E−07), GLS(0.011416), ALDH2(2.04E−05), PRODH2(1.88E−10), ALDH4A1(3.26E−08), DAO(5.49E−10), OAT(1.18E−06), ALDH9A1(7.68E−06)map00380Tryptophan metabolismMetabolism; amino acid metabolismUp0.0011918DDC(7.22E−06), GCDH(2.55E−07), KYNU(0.021680), MAOA(0.000363), EHHADH(0.009979), OGDHL(7.95E−10), ECHS1(1.41E−09), IDO1(5.75E−06), OGDH(0.015859), ACAT1(3.35E−05), ALDH3A2(0.001311), ALDH7A1(0.000678), ALDH1B1(1.21E−06), AOX1(0.000215), ALDH2(2.04E−05), CAT(0.000463), HADH(3.58E−10), ALDH9A1(7.68E−06)map00410beta-Alanine metabolismMetabolism; metabolism of other amino acidsUp0.0018312ALDH7A1(0.000678), ACADM(0.000825), ALDH1B1(1.21E−06), UPB1(0.030295), EHHADH(0.009979), ALDH2(2.04E−05), ABAT(8.77E−11), DPYS(3.24E−05), ECHS1(1.41E−09), HIBCH(3.29E−05), ALDH3A2(0.001311), ALDH9A1(7.68E−06)map00620Pyruvate metabolismMetabolism; carbohydrate metabolismUp1.34E−0623LDHB(9.05E−10), LDHA(5.38E−14), ME2(0.009738), ACACB(0.015700), GRHPR(0.000187), PCK2(3.66E−08), ACAT1(3.35E−05), ALDH3A2(0.001311), PDHB(3.11E−07), PCK1(8.90E−06), HAGH(1.21E−06), ALDH7A1(0.000678), ALDH1B1(1.21E−06), PKM2(1.23E−05), PKLR(0.000109), AKR1B1(0.023956), DLD(0.001570), ALDH2(2.04E−05), PDHA1(3.64E−07), ALDH9A1(7.68E−06), MDH2(0.041430), MDH1(3.71E−05), PC(4.74E−08)map00630Glyo ylate and dicarbo ylate metabolismMetabolism; carbohydrate metabolismUp0.019878MTHFD1(0.007709), MTHFD2(0.001166), ACO2(0.009461), ACO1(3.37E−08), HAO2(1.30E−07), GRHPR(0.000187), MDH2(0.041430), MDH1(3.71E−05)map00640Propanoate metabolismMetabolism; carbohydrate metabolismUp3.35E−0822ALDH6A1(1.54E−09), LDHB(9.05E−10), LDHA(5.38E−14), ACADM(0.000825), SUCLG2(0.001127), SUCLG1(7.68E−13), EHHADH(0.009979), ECHS1(1.41E−09), ACACB(0.015700), ACAT1(3.35E−05), ACSS3(0.016867), ALDH3A2(0.001311), ALDH7A1(0.000678), MUT(2.71E−05), ALDH1B1(1.21E−06), ALDH2(2.04E−05), ABAT(8.77E−11), HIBCH(3.29E−05), SUCLA2(0.002727), PCCB(4.63E−09), PCCA(1.72E−07), ALDH9A1(7.68E−06)map00650Butanoate metabolismMetabolism; carbohydrate metabolismUp5.21E−0620ACADS(0.000351), ALDH5A1(9.42E−06), EHHADH(0.009979), ECHS1(1.41E−09), ACAT1(3.35E−05), ALDH3A2(0.001311), PDHB(3.11E−07), ACSM3(0.000166), ALDH7A1(0.000678), HMGCS2(0.025830), ALDH1B1(1.21E−06), OXCT1(1.70E−06), ALDH2(2.04E−05), ABAT(8.77E−11), BDH2(2.94E−05), PDHA1(3.64E−07), HADH(3.58E−10), BDH1(1.61E−05), ALDH9A1(7.68E−06), HMGCL(2.12E−07)map00670One carbon pool by folateMetabolism; metabolism of cofactors and vitaminsUp0.007829MTHFD1(0.007709), TYMS(1.33E−06), MTHFS(5.33E−05), MTHFD2(0.001166), SHMT1(0.003744), SHMT2(4.22E−08), ALDH1L1(9.60E−05), AMT(3.71E−07), FTCD(9.75E−08)map03320PPAR signaling pathwayOrganismal systems; endocrine systemUp6.52E−0427ACOX2(9.21E−10), ACOX1(1.77E−07), CPT2(0.012060), EHHADH(0.009979), AQP7(7.03E−08), CYP4A22(5.91E−05), SORBS1(0.005358), APOC3(0.000893), ANGPTL4(6.66E−15), ACSL5(0.000549), ACADM(0.000825), SCD(2.00E−07), PCK2(3.66E−08), DBI(0.000967), CPT1A(0.028547), PCK1(8.90E−06), CYP4A11(3.26E−05), CD36(5.44E−06), HMGCS2(0.025830), FABP3(0.000589), FABP1(7.22E−12), GK(3.94E−07), FABP7(2.69E−05), SLC27A2(0.000151), FABP5(4.10E−10), FABP6(3.08E−06), ACAA1(6.20E−09)map04510Focal adhesionCellular processes; cell communicationDown0.03278153PGF(0.000247), PDGFA(0.019680), TLN2(2.47E−07), PTEN(0.003678), PAK2(0.000209), PAK4(0.002613), SHC1(0.000611), PDGFD(0.000349), PRKCA(2.22E−05), EGFR(1.41E−07), ACTN1(0.000296), FLNA(0.035792), PRKCB(0.021118), VEGFB(0.020498), VEGFC(0.026817), MAPK1(2.74E−05), CCND1(5.27E−09), CRKL(0.007581), CCND3(0.000176), CCND2(0.000658), JUN(0.013527), VEGFA(1.13E−09), COL1A2(0.000143), PDGFRA(3.14E−06), LAMC1(1.19E−05), COL1A1(0.003965), CAV2(3.20E−12), CAV1(2.03E−12), ERBB2(3.60E−05), COL3A1(0.017713), ITGB1(4.97E−06), RAC2(1.03E−05), BCL2(0.040852), COL6A2(0.000499), PIK3R3(0.002499), LAMB1(0.004054), EGF(4.00E−10), FN1(3.26E−07), COL4A4(2.16E−08), COL4A2(0.000133), FLT1(3.53E−06), VAV3(0.002113), COL4A1(4.37E−07), MET(6.32E−06), MAPK10(2.71E−07), BIRC3(3.98E−07), COL5A2(0.000159), COL4A6(7.63E−11), KDR(0.001381), LAMA2(0.000494), VWF(9.83E−10), LAMA4(6.92E−08), ITGA5(9.13E−07)map04512ECM--receptor interactionEnvironmental information processing; signaling molecules and interactionDown0.0257126COL3A1(0.017712), DAG1(0.000975), SDC4(0.006038), ITGB1(4.97E−06), SDC3(0.001060), CD47(0.000105), CD44(0.000548), COL6A2(0.000499), AGRN(0.040523), LAMB1(0.004054), FN1(3.26E−07), COL4A4(2.16E−08), COL4A2(0.000133), COL4A1(4.37E−07), HSPG2(0.001932), COL5A2(0.000159), COL4A6(7.63E−11), LAMA2(0.000494), VWF(9.83E−10), SDC1(0.040455), LAMA4(6.92E−08), CD36(5.44E−06), ITGA5(9.13E−07), COL1A2(0.000143), COL1A1(0.003965), LAMC1(1.19E−05)map04514Cell adhesion molecules (CAMs)Environmental information processing; signaling molecules and interactionDown5.95E−0444HLA-DQB1(0.000000), CLDN16(1.72E−08), CLDN8(0.000000), MPZL1(0.000543), CLDN10(2.25E−05), ITGB2(7.34E−10), L1CAM(1.08E−05), HLA-DMB(1.83E−06), SDC4(0.006038), ITGB1(4.97E−06), CDH4(0.032744), HLA-DMA(1.04E−07), CDH5(0.000118), ITGAM(9.55E−07), SDC3(0.001060), VCAM1(0.001385), HLA-DRB4(0.000000), CD2(0.000423), CD4(0.000493), HLA-DPB1(3.92E−08), SELPLG(3.67E−06), SPN(0.039304), ICAM1(0.000321), PTPRC(1.12E−05), PTPRM(0.003162), ICAM2(0.021949), NLGN1(0.000208), NFASC(1.88E−06), CD99(2.14E−07), HLA-C(3.59E−06), HLA-B(8.79E−07), CD40(2.68E−07), HLA-E(3.29E−06), HLA-G(7.03E−06), HLA-F(5.75E−07), SIGLEC1(0.002946), SDC1(0.040455), CD86(1.91E−07), CD34(0.005288), PECAM1(6.83E−07), CD58(0.013779), HLA-DPA1(3.32E−07), VCAN(7.27E−05), JAM3(0.039287), HLA-DRA(8.95E−06)map04610Complement and coagulation cascadesOrganismal systems; immune systemUp0.0036325C7(3.66E−07), C3AR1(6.36E−08), A2M(0.015678), C3(9.80E−07), C5(6.29E−10), C1S(0.032201), BDKRB2(0.002440), KLKB1(0.020648), SERPINA5(3.33E−16), SERPINE1(0.002613), CFI(0.024368), CFD(8.97E−06), KNG1(0.000000), PLAT(0.000362), F11(2.44E−09), CR2(4.58E−05), F8(0.006901), SERPING1(0.032058), PLG(1.90E−09), PROC(9.00E−07), C1QA(4.11E−08), VWF(9.83E−10), C1QB(1.61E−09), PROS1(0.024909), F2R(0.034193)map04612Antigen processing and presentationOrganismal systems; immune systemDown0.0060528HLA-DQB1(0.000000), PDIA3(0.039365), LGMN(0.002506), IFI30(0.006301), HLA-DMB(1.83E−06), HLA-DMA(1.04E−07), CANX(0.000217), CD74(0.000111), B2M(0.008700), TAPBP(6.91E−08), HSPA2(3.45E−06), TAP2(0.002398), TAP1(2.37E−08), HLA-DRB4(0.000000), HSPA6(1.12E−05), HSPA4(0.000390), CD4(0.000493), HLA-DPB1(3.92E−08), HSP90AA1(0.00004952), CREB1(0.039261), HLA-C(3.59E−06), CTSS(2.98E−06), HLA-B(8.79E−07), HLA-E(3.29E−06), HLA-G(7.03E−06), HLA-F(5.75E−07), HLA-DPA1(3.32E−07), CTSB(0.015631), HLA-DRA(8.95E−06)map04666Fc gamma R-mediated phagocytosisOrganismal systems; immune systemDown0.0371928WASF3(0.000154), MARCKSL1(0.009354), WASF2(1.25E−05), ASAP2(0.017588), PIP5K1B(6.36E−05), ASAP1(1.36E−06), ASAP3(0.000381), ARPC5(2.53E−06), DOCK2(2.13E−06), RAC2(1.03E−05), GSN(0.000397), INPP5D(1.39E−05), PPAP2A(0.005090), PIK3R3(0.002499), PRKCA(2.22E−05), PTPRC(1.12E−05), VAV3(0.002113), SPHK2(4.65E−09), LYN(3.36E−05), HCK(4.00E−08), PRKCB(0.021118), MAPK1(2.74E−05), ARPC1B(1.77E−05), CRKL(0.007581), FCGR2B(0.007829), FCGR2C(5.76E−05), PLCG2(6.23E−08), MARCKS(4.86E−07), FCGR2A(2.11E−07)map04940Type I diabetes mellitusHuman diseases; endocrine and metabolic diseasesDown0.0151116HLA-DQB1(0.000000), PRF1(9.91E−05), HLA-C(3.59E−06), HLA-B(8.79E−07), HLA-DMB(1.83E−06), HLA-E(3.29E−06), HLA-DMA(1.04E−07), HLA-G(7.03E−06), HLA-F(5.75E−07), CD86(1.91E−07), CPE(0.000140), HLA-DRB4(0.000000), HLA-DPA1(3.32E−07), HLA-DPB1(3.92E−08), HSPD1(0.002241), FAS(0.000865), HLA-DRA(8.95E−06)map05010Alzheimer's diseaseHuman diseases; neurodegenerative diseasesUp0.0152546HSD17B10(1.92E−07), UQCRC1(1.72E−10), NDUFB8(0.026633), ATP5B(0.000025), COX7B(5.76E−05), SNCA(8.65E−05), MME(5.58E−07), ATP5G1(0.000552), UQCRFS1(4.82E−08), COX5A(9.06E−06), COX5B(0.005213), ATP5G3(5.48E−05), NDUFB1(1.20E−06), NDUFS7(0.005646), TNFRSF1A(0.018183), CASP3(0.001836), APOE(0.002175), CALML3(6.10E−05), NDUFS8(0.000199), FAS(0.000865), CHP(1.02E−05), NDUFS3(0.001237), PLCB1(0.000313), GAPDH(1.55E−06), NDUFS2(9.52E−07), NDUFS1(0.000719), NDUFA4(6.21E−12), NDUFA3(0.000707), ADAM10(0.001821), NDUFA4L2(0.000000), NDUFA6(3.74E−06), COX8A(2.45E−06), CYCS(0.000302), NDUFA10(0.002332), ITPR3(0.001233), ITPR2(4.78E−09), MAPK1(2.74E−05), SDHB(0.000273), ATP2A2(0.003118), UQCRH(0.008671), NDUFV1(9.75E−06), SDHC(0.002922), SDHD(0.002733), ATP5C1(2.40E−06), ATP5A1(1.85E−07), UQCRB(0.000496)map05012Parkinson's diseaseHuman diseases; neurodegenerative diseasesUp5.80E−0443UQCRC1(1.72E−10), NDUFB8(0.026633), ATP5B(0.000025), SLC6A3(3.26E−05), SNCA(8.65E−05), UCHL1(0.000664), COX7B(5.76E−05), PINK1(0.009949), ATP5G1(0.000552), UQCRFS1(4.82E−08), COX5A(9.06E−06), COX5B(0.005213), ATP5G3(5.48E−05), NDUFB1(1.20E−06), NDUFS7(0.005646), CASP3(0.001836), HTRA2(0.016642), NDUFS8(0.000199), NDUFS3(0.001237), NDUFS2(9.52E−07), NDUFS1(0.000719), NDUFA4(6.21E−12), NDUFA3(0.000707), SLC25A4(0.001148), SLC25A5(5.04E−09), NDUFA4L2(0.000000), NDUFA6(3.74E−06), COX8A(2.45E−06), CYCS(0.000302), UBE2J1(0.002195), UBE2L6(1.49E−07), NDUFA10(0.002332), SDHB(0.000273), UBA1(0.018511), UQCRH(0.008671), SDHC(0.002922), NDUFV1(9.75E−06), PPID(0.016505), SDHD(0.002733), ATP5C1(2.40E−06), ATP5A1(1.85E−07), UBB(1.00E−04), UQCRB(0.000496)map05110Vibrio cholerae infectionHuman diseases; infectious diseasesUp0.0122320PRKCA(2.22E−05), TCIRG1(2.68E−06), ADCY3(2.20E−06), KDELR2(0.002836), ATP6V1H(2.04E−09), PDIA4(0.013818), ATP6V1B2(0.020631), ATP6V1B1(8.54E−11), ATP6V1D(2.09E−05), ATP6V0B(3.18E−07), PRKCB(0.021118), ATP6V0C(0.001556), ATP6V1A(0.000647), ATP6V0E2(1.46E−07), PLCG2(6.23E−08), ERO1L(5.50E−06), ATP6V0D1(0.000687), ATP6V0A4(1.33E−15), KCNQ1(2.22E−06), SEC61G(3.22E−11)map05120Epithelial cell signaling in Helicobacter pylori infectionHuman diseases; infectious diseasesUp0.0262122EGFR(1.41E−07), TCIRG1(2.68E−06), ADAM10(0.001821), LYN(3.36E−05), MET(6.32E−06), ATP6V1H(2.04E−09), ATP6V1B2(0.020631), MAPK10(2.71E−07), ATP6V1B1(8.54E−11), CCL5(0.000176), ATP6V1D(2.09E−05), ATP6V0B(3.18E−07), ATP6V0C(0.001556), ATP6V1A(0.000647), CASP3(0.001836), ATP6V0E2(1.46E−07), JUN(0.013527), PLCG2(6.23E−08), ATP6V0A4(1.33E−15), ATP6V0D1(0.000687), JAM3(0.039287), CHUK(0.001478)map05212Pancreatic cancerHuman diseases; cancersDown0.0066925PGF(0.000247), ERBB2(3.60E−05), TGFB1(1.25E−05), ACVR1B(0.020268), CDKN2A(6.57E−07), RAC2(1.03E−05), RALB(0.003717), TGFA(4.14E−06), EGF(4.00E−10), PIK3R3(0.002499), CHUK(0.001478), EGFR(1.41E−07), RALBP1(0.017196), ARHGEF6(1.56E−07), TP53(0.015394), MAPK10(2.71E−07), RB1(1.23E−05), STAT1(0.008747), RALGDS(0.001720), VEGFB(0.020498), VEGFC(0.026817), MAPK1(2.74E−05), CCND1(5.27E−09), VEGFA(1.13E−09), JAK1(0.003297)map05219Bladder cancerHuman diseases; cancersDown0.0061217EGFR(1.41E−07), FGFR3(0.004060), PGF(0.000247), ERBB2(3.60E−05), MMP9(0.013659), TP53(0.015394), RB1(1.23E−05), VEGFB(0.020498), VEGFC(0.026817), MAPK1(2.74E−05), TYMP(9.37E−07), CCND1(5.27E−09), CDKN1A(0.004616), CDKN2A(6.57E−07), VEGFA(1.13E−09), EGF(4.00E−10), MYC(9.64E−06)map05222Small cell lung cancerHuman diseases; cancersDown0.0257126CKS1B(5.60E−06), FHIT(3.52E−07), PTEN(0.003678), ITGB1(4.97E−06), BCL2(0.040852), PIK3R3(0.002499), LAMB1(0.004054), MYC(9.64E−06), TRAF5(0.010154), CHUK(0.001478), FN1(3.26E−07), COL4A4(2.16E−08), COL4A2(0.000133), COL4A1(4.37E−07), CYCS(0.000302), TP53(0.015394), SKP2(0.001476), RB1(0.041380), BIRC3(3.98E−07), COL4A6(7.63E−11), LAMA2(0.000494), LAMA4(6.92E−08), CCND1(5.27E−09), CDKN1B(8.75E−05), PIAS1(0.019851), LAMC1(1.19E−05)map05320Autoimmune thyroid diseaseHuman diseases; immune diseasesDown0.0801416HLA-DQB1(0.000000), TG(0.001762), PRF1(9.91E−05), HLA-C(3.59E−06), CD40(2.68E−07), HLA-B(8.79E−07), HLA-DMB(1.83E−06), HLA-E(3.29E−06), HLA-DMA(1.04E−07), HLA-G(7.03E−06), HLA-F(5.75E−07), CD86(1.91E−07), HLA-DRB4(0.000000), HLA-DPA1(3.32E−07), HLA-DPB1(3.92E−08), FAS(0.000865), HLA-DRA(8.95E−06)map05322Systemic lupus erythematosusHuman diseases; immune diseasesDown0.0930727HLA-DQB1(0.000000), C7(3.80E−07), C3(9.80E−07), C5(6.29E−10), SNRPD1(0.000590), C1S(0.032201), HLA-DMB(1.83E−06), HLA-DMA(1.04E−07), HIST1H2BK(1.05E−05), HLA-DRB4(0.000000), H2AFZ(0.001992), H2AFY(0.011433), HIST1H4C(0.025179), HLA-DPB1(3.92E−08), FCGR3B(8.53E−06), HIST1H2BE(0.009017), ACTN1(0.000296), CD40(2.68E−07), TRIM21(0.000120), C1QA(4.11E−08), C1QB(1.61E−09), CD86(1.91E−07), FCGR2B(0.007829), FCGR2C(5.76E−05), H2AFY2(0.000330), HLA-DPA1(3.32E−07), FCGR2A(2.11E−07), HLA-DRA(8.95E−06)map05330Allograft rejectionHuman diseases; immune diseasesDown0.0081815HLA-DQB1(0.000000), PRF1(9.91E−05), HLA-C(3.59E−06), CD40(2.68E−07), HLA-B(8.79E−07), HLA-DMB(1.83E−06), HLA-E(3.29E−06), HLA-DMA(1.04E−07), HLA-G(7.03E−06), HLA-F(5.75E−07), CD86(1.91E−07), HLA-DRB4(0.000000), HLA-DPA1(3.32E−07), HLA-DPB1(3.92E−08), FAS(0.000865), HLA-DRA(8.95E−06)map05332Graft-versus-host diseaseHuman diseases; immune diseasesDown0.0403114HLA-DQB1(0.000000), PRF1(9.91E−05), HLA-C(3.59E−06), HLA-B(8.79E−07), HLA-DMB(1.83E−06), HLA-E(3.29E−06), HLA-DMA(1.04E−07), HLA-G(7.03E−06), HLA-F(5.75E−07), CD86(1.91E−07), HLA-DRB4(0.000000), HLA-DPA1(3.32E−07), FAS(0.000865), HLA-DPB1(3.92E−08), HLA-DRA(8.95E−06)map05416Viral myocarditisHuman diseases; cardiovascular diseasesDown0.0010727HLA-DQB1(0.000000), PRF1(9.91E−05), CAV1(2.03E−12), DAG1(0.000975), ITGB2(7.34E−10), HLA-DMB(1.83E−06), HLA-DMA(1.04E−07), CASP3(0.001836), RAC2(1.03E−05), HLA-DRB4(0.000000), HLA-DPB1(3.92E−08), ICAM1(0.000321), CYCS(0.000302), HLA-C(3.59E−06), CD40(2.68E−07), HLA-B(8.79E−07), MYH9(0.011717), HLA-E(3.29E−06), MYH8(0.014687), HLA-G(7.03E−06), HLA-F(5.75E−07), LAMA2(0.000494), CD86(1.91E−07), CCND1(5.27E−09), HLA-DPA1(3.32E−07), MYH14(0.000268), HLA-DRA(8.95E−06), MYH10(0.002797)

Discussion {#Sec10}
==========

Clear cell renal cell carcinoma is one of the most common types of kidney cancer in adult; however, its causes are not completely understood. The selection of differentially expressed genes and consistent pathways helps us to explore their underlying molecular mechanisms, thereby providing insights into biological function. Single gene-marker-based approaches can fail to detect transcriptional programs that are distributed across an entire network of genes are yet subtle at the level of individual gene \[[@CR15]\]. Genome-wide microarrays can locate gene families and pathways which show a consistent alteration in a disease state. Pathway analysis is a valid method to reduce a major deviation and can obtain interesting common genes and pathways by mixing differently expressed genes from different datasets.

Some studies have been published. The study of Tun et al. \[[@CR16]\] used gene expression profiling of early-stage ccRCC combined with a comprehensive bioinformatics analyses to reveal the significant pathway and transcription factors which take effect in the development of ccRCC. Meanwhile, Maruschke et al. \[[@CR17]\] used microarray expression analysis to determine 16 gene sets that distinguish expression profiles from grade 1 and grade 3 tumor tissues based on MSigDB data bank analysis. The two studies above were single dataset analysis. However, multi-microarray dataset analysis for the development of ccRCC was rare. This study uses three datasets based on a novel GSEA carried out by KEGG dataset and meta-analysis approach to identify the common significant genes and genetic pathways with *p* \< 0.05 associated ccRCC. And our findings suggest that most genes and pathways involved in ccRCC are the same according to their functional classification. In this study, we discussed several differentially expressed pathways and genes among crossing pathways which suggest the role of these pathways and genes in ccRCC based on their functional classification.

Metabolism pathways {#Sec11}
-------------------

The metabolism pathways in our study were predominantly focused on carbohydrate metabolism, lipid metabolism, energy metabolism, amino acid metabolism, metabolism of other amino acids, metabolism of cofactors and vitamins. ccRCC is increasingly being recognized as a metabolic disease. Numerous studies have shown a significant association between body mass index, obesity and the development of kidney cancer \[[@CR18]\]. In a case--control study from Iowa, diets richest in animal and saturated fats, oleic acid and cholesterol were associated with statistically significant increases in RCC (1.9--2.6-fold, depending on the factor) \[[@CR19]\]. These metabolic abnormalities provide protection for the tumor but also may provide a source of vulnerability and therapeutic opportunity. Citrate cycle (TCA cycle) discovered in this study belongs to Carbohydrate metabolism; it is part of a metabolic pathway coupled to mitochondrial oxidative phosphorylation that converts nutrients to energy in aerobic cells. Recently, heterozygous germline mutations in fumarate hydratase (FH) or succinate dehydrogenase (SDH) of the TCA cycle have been shown to predispose individuals to tumors \[[@CR20]\]. SDHB/C/D is the key gene in the Citrate cycle and oxidative phosphorylation pathway in our article. SDH is one of the seven known kidney cancer genes involved in pathways that respond to metabolic stress and/or nutrient stimulation \[[@CR21]\]. Targeting the fundamental metabolic abnormalities in kidney cancer provides a unique opportunity for the development of more effective forms of therapy for this disease. Recently, early-onset renal tumors have been found to develop in individuals with germ line SDHB mutations \[[@CR22], [@CR23]\]. In preclinical models, increased succinate has been shown to inhibit HIF prolyl hydroxylase and affect HIF stability \[[@CR24]\]. HIF can strengthen the expression of vascular endothelial growth factor (VEGF), glucose transcript factor 1 (GLUT-1) and glycolytic enzyme in the downstream target genes; promote the generation of blood vessels and energy metabolism of cells; and possibly play an important role in the developing progress in the excessive expression of malignant tumor \[[@CR25], [@CR26]\].

Cellular processes and cell communication {#Sec12}
-----------------------------------------

Focal adhesion pathway (Fig. [1](#Fig1){ref-type="fig"}) in our result belongs to cellular processes and cell communication. In cell biology, focal adhesions (cell--matrix adhesions or FAs) are specific types of large macromolecular assemblies through which both mechanical force and regulatory signals are transmitted. Cell--matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival \[[@CR27]\]. Tumor epithelial and endothelial cells require attachment to the extracellular matrix (ECM) for survival; on loss of adhesion, they undergo anoikis \[[@CR28], [@CR29]\]. Quinazoline-based drugs trigger anoikis in renal cancer cells by targeting the focal adhesion survival signaling. This potent antitumor action against human RCC suggests a novel quinazoline-based therapy targeting renal cancer \[[@CR30]\]. VEGFA/B/C (marked by red stars in Fig. [1](#Fig1){ref-type="fig"}) is significant gene in focal adhesion pathway. The role of VEGF in particular has been explored as a key factor in the pathogenesis of RCC. VEGF functions to increase vascular permeability, induce endothelial cell proliferation and migration, and promote endothelial cell survival \[[@CR31]\]. Furthermore, VEGF receptor expression has been observed in RCC cells, suggesting that VEGF may also serve as an autocrine stimulus in RCC \[[@CR32]\]. The high VEGF expression in RCC is the direct result of inactivation of the Von Hippel--Lindau tumor suppressor gene (VHL). Data suggest that VHL inactivation occurs in the majority of ccRCC \[[@CR33]\]. Therapeutic targeting of VEGF in RCC has strong biologic rationale. Substantial clinical activity has been reported in clinical trials with VEGF-targeting agents \[[@CR34], [@CR35]\]. Further investigation is needed to optimally use these agents for maximal clinical benefit.Fig. 1Focal adhesion pathway (the chart is from the KEGG database, ★*p* \< 0.05, genes symbolized by ★ and correlation *p* values can be found in map04510 of Table [4](#Tab4){ref-type="table"})

Environmental information processing {#Sec13}
------------------------------------

Extracellular matrix--receptor interaction and cell adhesion molecule (CAM) pathways were in this classification. They are all about signaling molecules and interaction. The extracellular matrix (ECM) consists of a complex mixture of structural and functional macromolecules and serves an important role in tissue and organ morphogenesis and in the maintenance of cell and tissue structure and function \[[@CR36]\]. There is close connection between ECM--receptor interaction and focal adhesion pathway, which is also a significant pathway. At the cell--extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins \[[@CR37]\]. There is increasing evidence that certain integrins associate with receptor tyrosine kinases (RTKs) to activate signaling pathways that are necessary for tumor invasion and metastasis \[[@CR38]\]. Zhou et al. \[[@CR39]\] found that multiple canonical cancer-associated signaling pathways including focal adhesion, cell cycle and ECM--receptor interaction were significantly more likely to be disrupted in ccRCC than expected by chance. This is consistent with the results of our study.

CD47 is a key gene in ECM--receptor interaction pathway, which is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. As has been found by other investigators, CD47 over expression may be associated with ferric nitrilotriacetate-induced renal cortical tubular damage and regeneration that lead to a polycystic state, and with tumor progression and metastasis of the induced RCCs \[[@CR40]\].

Other pathways and genes {#Sec14}
------------------------

Human diseases and organismal systems are the two remaining classifications associated with ccRCC. Pathways such as type I diabetes mellitus, epithelial cell signaling in helicobacter pylori infection, bladder cancer, systemic lupus erythematosus and so on all belonged to the classification of human diseases. They are mainly about endocrine and metabolic diseases, neurodegenerative diseases, infectious diseases, cancers, immune diseases and cardiovascular diseases. Some diseases above belong to endocrine or immune system organic system in the classification of organismal systems. Most of genes in these pathways can be enriched in the above pathways. HLA-DQB1 appears in 8 pathways in human diseases, organismal systems and environmental information processing classification is an important gene for ccRCC, and this has widely been reported in the literature. Patients with RCC whose tumors did not express HLA-DQA1 or HLA-DQB1 molecules demonstrated poor clinical response \[[@CR41]\]. EGFR and VEGFA/B/C expression in human disease pathways play an important regulatory role in tumor angiogenesis, invasion and metastasis. Based on the EGFR/VEGF target in the treatment of cancer is the hot spot in drug research \[[@CR42]\].

Conclusion {#Sec15}
==========

The pathogenesis of ccRCC is quite complicated. It is effective to identify differentially expressed genes and deduce their underlying molecular pathways based on gene set enrichment analysis and meta-analysis. The significant genes and pathways were mainly focused on metabolism, cellular processes and cell communication, environmental information processing, human diseases and organismal systems. They may have some connections with ccRCC. Furthermore, we verified some of the results by searching the literature in the discussion section. The conclusion is relatively reliable and can be used to guide further study. Further experiments are needed to verify specific links between these results and ccRCC.
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